Glucocorticoid-mediated effects on metabolism are reversed by targeting 11 beta hydroxysteroid dehydrogenase type 1 in human skeletal muscle

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 3, 2009, Pages 250-258

  Salehzadeh, Firoozeh ^a   Al Khalili, Lubna ^a   Kulkarni, Sameer S ^a   Wang, Minghan ^b   Lönnqvist, Fredrik ^c   Krook, Anna ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b AMGEN INC   (United States)

^c BIOVITRUM AB   (Sweden)

Author keywords

Cell culture; Glucocorticoids; Glucose metabolism; Human skeletal muscle; Palmitate oxidation; Pyruvate dehydrogenase kinase 4

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CORTISONE; GLUCOCORTICOID; HYDROCORTISONE; MESSENGER RNA; MYOCYTE ENHANCER FACTOR 2A; MYOCYTE ENHANCER FACTOR 2C; MYOCYTE ENHANCER FACTOR 2D; PALMITIC ACID; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE KINASE 4; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; GLUCOSE;

ADULT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; FATTY ACID OXIDATION; GENE EXPRESSION; GENE TARGETING; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MUSCLE BIOPSY; MUSCLE DEVELOPMENT; MUSCLE GROWTH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKELETAL MUSCLE; CELL DIFFERENTIATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; CELL DIFFERENTIATION; CELLS, CULTURED; CORTISONE; GENE EXPRESSION; GLUCOCORTICOIDS; GLUCOSE; HUMANS; HYDROCORTISONE; MIDDLE AGED; MUSCLE, SKELETAL; PALMITIC ACID; RNA, SMALL INTERFERING;

EID: 65649147217     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.944     Document Type: Article

References (48)

1. Chapman K, Seckl J. 11β-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function. Neurochem Res 2008; 33: 624-636.
2. Qi D, Rodrigues B. Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab 2007; 292: E654-E667.
3. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007; 157: 545-559.
4. Wang M. The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr Metab 2005; 2: 3.
5. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999; 96: 513-523.
6. Björntorp P, Rosmond R. Obesity and cortisol. Nutrition 2000; 16: 924-936.
7. Holt HB, Wild SH, Postle AD, et al. Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men. Diabetologia 2007; 50: 1024-1032.
8. Bjorntörp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus. Diabet Med 1999; 16: 373-383.
9. Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-1421.
10. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JMC. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999; 33: 1364-1368.
11. Marin P, Darin N, Amemiya T, Andersson B, Jern S, Björntorp P. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 1992; 41: 882-886.
12. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM. Immunohistochemical localization of type 1 11 beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 1998; 83: 1325-1335.
13. Draper N, Stewart PM. 11 Beta-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 2005; 186: 251-271.
14. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A 1997; 94: 14924-14929.
15. Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004; 53: 931-938.
16. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170.
17. DeFronzo RA, Jocot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Diabetes 1981; 30: 1000-1007.
18. Abdallah BM, Beck-Nielsen H, Gaster M. Increased expression of 11beta;-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur J Clin Invest 2005; 35: 627-634.
19. Whorwood CB, Donovan SJ, Flanagan D, Phillips DIW, Byrne CD. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 2002; 51: 1066-1075.
20. Jang C, Obeyesekere VR, Dilley RJ, Krozowski Z, Inder WJ, Alford FP. Altered activity of 11 beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes. J Clin Endocrinol Metab 2007; 92: 3314-3320.
21. St. Jean DJ, Yuan C, Bercot EA, et al. 2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11 beta-hydroxysteriod dehydrogenase type 1. J Med Chem 2007; 50: 429-432.
22. Hale C, Véniant M, Wang Z, et al. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor. Chem Biol Drug Des 2008; 71: 36-44.
23. Al-Khalili L, Chibalin AV, Kannisto K, et al. Insulin action in cultured human skeletal muscle cells during differentiation: assessment of cell surface GLUT4 and GLUT1 content. Cell Mol Life Sci 2003; 60: 991-998.
24. Bouzakri K, Zachrisson A, Al-Khalili L, et al. siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism in human skeletal muscle. Cell Metab 2006; 4: 89-96.
25. Al-Khalili L, Bouzakri K, Glund S, Lönnqvist F, Koistinen HA, Krook A. Signalling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 2006; 20: 3364-3375.
26. Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CR. Mineralocorticoid excess and inhibition of 11beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) 1992; 37: 483-492.
27. Shafqat N, Elleby B, Svensson S, et al. Comparative enzymology of 11beta -hydroxysteroid dehydrogenase type 1 from glucocorticoid resistant (Guinea Pig) versus sensitive (human) species. J Biol Chem 2003; 278: 2030-2035.
28. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25: 831-866.
29. Stimson RH, Andersson J, Andrew R, et al. Cortisol release from adipose tissue by 11{beta}-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009; 58: 46-53.
30. Jang C, Obeyesekere VR, Dilley RJ, Alford FP, Inder WJ. 11betaHydroxysteroid dehydrogenase type 1 is expressed and is biologically active in human skeletal muscle. Clin Endocrinol 2006; 65: 800-805.
31. Tomlinson JW, Stewart PM. Mechanisms of disease: selective inhibition of 11-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat Clin Pract Endocrinol Metabol 2005; 1: 92-99.
32. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997; 349: 1210-1213.
33. Nair S, Lee YH, Lindsay RS, et al. 11β-hydroxysteroid dehydrogenase type 1: genetic polymorphisms are associated with type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia 2004; 47: 1088-1095.
34. Franks PW, Knowler WC, Nair S, et al. Interaction between an 11 beta-HSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians. Hypertension 2004; 44: 681-688.
35. Hammami MM, Siiteri PK. Regulation of 11 beta-hydroxysteroid dehydrogenase activity in human skin fibroblasts: enzymatic modulation of glucocorticoid action. J Clin Endocrinol Metab 1991; 73: 326-334.
36. Sun K, Myatt L. Enhancement of glucocorticoid-induced 11beta-hydroxysteroid dehydrogenase type 1 expression by proinflammatory cytokines in cultured human amnion fibroblasts. Endocrinology 2003; 144: 5568-5577.
37. Rajan V, Edwards CRW, Seckl JR. 11 beta-Hydroxysteroid dehydrogenase in cultured hippocampal cells reactivates inert 11-dehydrocorticosterone, potentiating neurotoxicity. J Neurosci Nurs 1996; 16: 65-70.
38. Huang B, Wu P, Bowker-Kinley MM, Harris RA. Regulation of pruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes 2002; 51: 276-283.
39. Komamura K, Shirotani-Ikejima H, Tatsumi R, et al. Differential gene expression in the rat skeletal and heart muscle in glucocorticoid-induced myopathy: analysis by microarray. Cardiovasc Drugs Ther 2003; 17: 303-310.
40. Sun L, Nicholson AC, Hajjar DP, Gotto AM Jr, Han J. Adipogenic differentiating agents regulate expression of fatty acid binding protein and CD36 in the J744 macrophage cell line. J Lipid Res 2003; 44: 1877-1886.
41. Block NE, Buse MG. Effects of hypercortisolemia and diabetes on skeletal muscle insulin receptor function in vitro and in vivo. Am J Physiol Endocrinol Metab 1989; 256: E39-E48.
42. Giorgino F, Almahfouz A, Goodyear LJ, Smith RJ. Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. J Clin Invest 1993; 91: 2020-2030.
43. Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 2005; 48: 2119-2130.
44. Saad MJ, Folli F, Kahn JA, Kahn CR. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 1993; 92: 2065-2072.
45. Randle PJ. Fuel selection in animals. Biochem Soc Trans 1986; 14: 799-806.
46. Jeoung NH, Harris RA. Pyruvate dehydrogenase kinase 4 (PDK4) deficiency lowers blood glucose and improves glucose tolerance in diet-induced obese mice. Am J Physiol Endocrinol Metab 2008; 295: E46-54.
47. Wang M. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Curr Opin Investig Drugs 2006; 7: 319-323.
48. Hale C, Wang M. Development of 11 beta-HSD1 Inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem 2008; 7: 702-710.